[go: up one dir, main page]

MX2018011379A - Tratamiento del prurito uremico. - Google Patents

Tratamiento del prurito uremico.

Info

Publication number
MX2018011379A
MX2018011379A MX2018011379A MX2018011379A MX2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A
Authority
MX
Mexico
Prior art keywords
prurite
uremic
treatment
patient
methods
Prior art date
Application number
MX2018011379A
Other languages
English (en)
Other versions
MX382608B (es
Inventor
Sciascia Thomas
Good Jennifer
Hawi Amale
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2018011379A publication Critical patent/MX2018011379A/es
Publication of MX382608B publication Critical patent/MX382608B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos para tratar el prurito urémico con composiciones antipruríticas, en donde el método proporciona un efecto terapéutico en un paciente.
MX2018011379A 2016-03-21 2017-03-21 Tratamiento del prurito urémico. MX382608B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311134P 2016-03-21 2016-03-21
US201662412584P 2016-10-25 2016-10-25
PCT/US2017/023398 WO2017165409A1 (en) 2016-03-21 2017-03-21 Treatment of uremic pruritus

Publications (2)

Publication Number Publication Date
MX2018011379A true MX2018011379A (es) 2019-06-13
MX382608B MX382608B (es) 2025-03-13

Family

ID=59899743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011379A MX382608B (es) 2016-03-21 2017-03-21 Tratamiento del prurito urémico.

Country Status (11)

Country Link
US (1) US20180008592A1 (es)
EP (1) EP3432871B1 (es)
JP (2) JP2019509309A (es)
KR (1) KR20180120756A (es)
CN (1) CN109310656A (es)
AU (1) AU2017238051B9 (es)
BR (1) BR112018069174A2 (es)
CA (1) CA3017374A1 (es)
ES (1) ES2970294T3 (es)
MX (1) MX382608B (es)
WO (1) WO2017165409A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672743A (zh) * 2018-07-11 2021-04-16 特雷维治疗股份有限公司 肝病瘙痒症状的治疗
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
WO2021222886A1 (en) * 2020-05-01 2021-11-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to treat polycystic kidney disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215158T3 (es) * 1996-11-25 2004-10-01 Toray Industries, Inc. Agente antipruritico.
US20090093509A1 (en) * 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
US8686040B2 (en) * 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
EP2931279B1 (en) * 2012-12-14 2024-03-20 Trevi Therapeutics, Inc. Methods for treating pruritus
CN106535897A (zh) * 2014-06-13 2017-03-22 特雷维治疗股份有限公司 用于治疗瘙痒的方法

Also Published As

Publication number Publication date
AU2017238051B9 (en) 2022-11-03
ES2970294T3 (es) 2024-05-27
CN109310656A (zh) 2019-02-05
CA3017374A1 (en) 2017-09-28
AU2017238051A1 (en) 2018-10-04
EP3432871B1 (en) 2023-11-15
WO2017165409A1 (en) 2017-09-28
BR112018069174A2 (pt) 2019-01-29
EP3432871A1 (en) 2019-01-30
AU2017238051B2 (en) 2022-10-06
US20180008592A1 (en) 2018-01-11
EP3432871A4 (en) 2019-10-30
MX382608B (es) 2025-03-13
KR20180120756A (ko) 2018-11-06
JP2019509309A (ja) 2019-04-04
JP2022081640A (ja) 2022-05-31

Similar Documents

Publication Publication Date Title
PH12015502075A1 (en) Treatment of cataplexy
MX384240B (es) Bacterias probioticas recombinantes.
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
MX2017011374A (es) Método de tratamiento de cáncer asociado con una mutación de ras.
MY194341A (en) Method of treating a brain tumor
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
EA201791110A1 (ru) Сублингвальное введение рилузола
PH12016502150A1 (en) Method for treating renal cell carcimona
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017000306A (es) Metodos para tratar hipotension.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2018011379A (es) Tratamiento del prurito uremico.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX376191B (es) Composicion hiperosmolar de acido hialuronico.
MX2016002307A (es) Tratamiento para el cancer.
EA201690446A1 (ru) Лечение множественной миеломы
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
MX2017013669A (es) Composiciones para el tramiento del cancer.
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии